What's Hot in Cardiology beyond DES? Try Structural Heart Disease

Structural heart disease was prominently featured during the Emerging Technologies Symposium held during this year's Summer in Seattle cardiovascular conference.

The ever-increasing number of clinical conferences, particularly in cardiology, can sometimes take on a mind-numbing sameness as attendees sit through the presentation of still another patient subset of a drug-eluting stent (DES). What distinguishes the annual Summer in Seattle meeting is the Emerging Technologies Symposium held as part of the conference, at which future areas of interest within cardiology are identified and early-stage companies active in that space are given the opportunity to make presentations. Mark Reisman, MD, of Seattle's Swedish Medical Center, and William A. Gray, MD, of Columbia University Medical Center , the conference directors, have been successful in highlighting the next and the next-next areas of interest in cardiovascular medicine and have been able to attract very early-stage companies to discuss those areas, no small feat when it comes to device start-ups.

The fifth annual conference, held this July, highlighted a range of topics from vascular technologies such as bioabsorbable DES to...

More from Innovation

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.